Shire Pharmaceuticals Group Plc

Patent Trial and Appeal Board Upholds the Validity of LIALDA® Patent

Lexington, Massachusetts (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued their decision upholding the validity of U.S. Patent No. 6,773,720, related to Shire's LIALDA® (mesalamine) product.

The petition seeking to institute inter partes review (IPR) was filed with the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) in April of 2015 by the Coalition For Affordable Drugs (CFAD) II L.L.C. Fund. The PTAB found that the patent was valid in light of the challenges put forward by the petitioner.

Shire is pleased with the decision and will continue to vigorously defend its patents to protect the innovation and value Shire products bring to patients.

LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of UC. There have not been any approvals of generic versions of LIALDA.

Indication

Lialda is a prescription medication approved for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Do not take Lialda (mesalamine) if you are allergic to salicylates, such as aspirin, or medications that contain aspirin; aminosalicylates; mesalamine; or any other ingredients in Lialda.

Tell your doctor if you:

- have or have had kidney problems. Kidney problems have been 
  reported with medications that contain mesalamine, such as Lialda. 
  Your doctor may check to see how your kidneys are working before 
  starting Lialda and periodically while taking Lialda.
- have symptoms including cramping, stomach ache, bloody diarrhea, 
  fever, headache, and rash. Medications that contain mesalamine, 
  such as Lialda, have been associated with a condition that may be 
  hard to tell apart from a UC flare. Call your doctor right away if 
  you have any of these symptoms. He or she may tell you to stop 
  taking Lialda.
- are allergic to sulfasalazine, as you may also be allergic to 
  Lialda or medications that contain mesalamine.
- have or have had heart-related allergic reactions, such as 
  inflammation of the heart muscle (myocarditis) or the lining of the
  heart (pericarditis). These reactions have been seen in patients 
  taking Lialda or medications that contain mesalamine. Your chance 
  of having these types of reactions may increase when taking Lialda.
- have or have had liver problems. Problems with liver function have 
  been reported in patients who have or have had liver problems and 
  were taking medications that contain mesalamine, such as Lialda.
- have a stomach blockage. It may take longer for Lialda to start 
  working. 

The most common side effects reported in clinical studies of Lialda were:

- ulcerative colitis
- headache
- passing gas
- abnormal liver function test results
- stomach ache 

In clinical studies of Lialda, inflammation of the pancreas also occurred. If this happens to you, your doctor may tell you to stop taking Lialda.

Other side effects may occur.

Before starting Lialda, tell your doctor about all medications you are taking, including:

- non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen 
  and naproxen. Taking these medications with Lialda may increase 
  your chance of kidney problems.
- azathioprine and 6-mercaptopurine. Taking these medications with 
  Lialda may increase your chance of blood disorders. 

Please see Full Prescribing Information (http://pi.shirecontent.com/?product=LIALDA&country=USA&language=ENG) for Lialda (mesalamine)

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

http://www.shire.com

Forward-Looking Statements

Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:

- Shire's products may not be a commercial success;
- increased pricing pressures and limits on patient access as a 
  result of governmental regulations and market developments may 
  affect Shire's future revenues, financial condition and results of 
  operations;
- Shire conducts its own manufacturing operations for certain of its 
  products and is reliant on third party contract manufacturers to 
  manufacture other products and to provide goods and services.  Some
  of Shire's products or ingredients are only available from a single
  approved source for manufacture.  Any disruption to the supply 
  chain for any of Shire's products may result in Shire being unable 
  to continue marketing or developing a product or may result in 
  Shire being unable to do so on a commercially viable basis for some
  period of time;
- the manufacture of Shire's products is subject to extensive 
  oversight by various regulatory agencies.  Regulatory approvals or 
  interventions associated with changes to manufacturing sites, 
  ingredients or manufacturing processes could lead to significant 
  delays, an increase in operating costs, lost product sales, an 
  interruption of research activities or the delay of new product 
  launches;
- certain of Shire's therapies involve lengthy and complex processes,
  which may prevent Shire from timely responding to market forces and
  effectively managing its production capacity;
- Shire has a portfolio of products in various stages of research and
  development. The successful development of these products is highly
  uncertain and requires significant expenditures and time, and there
  is no guarantee that these products will receive regulatory 
  approval;
- the actions of certain customers could affect Shire's ability to 
  sell or market products profitably. Fluctuations in buying or 
  distribution patterns by such customers can adversely affect 
  Shire's revenues, financial conditions or results of operations;
- Shire's products and product candidates face substantial 
  competition in the product markets in which it operates, including 
  competition from generics;
- adverse outcomes in legal matters, tax audits and other disputes, 
  including Shire's ability to enforce and defend patents and other 
  intellectual property rights required for its business, could have 
  a material adverse effect on the combined company's revenues, 
  financial condition or results of operations;
- inability to successfully compete for highly qualified personnel 
  from other companies and organizations;
- failure to achieve the strategic objectives with respect to Shire's
  acquisition of NPS Pharmaceuticals, Inc., Dyax Corp. ("Dyax") or 
  Baxalta Inc. ("Baxalta")may adversely affect Shire's financial 
  condition and results of operations;
- Shire's growth strategy depends in part upon its ability to expand 
  its product portfolio through external collaborations, which, if 
  unsuccessful, may adversely affect the development and sale of its 
  products;
- a slowdown of global economic growth, or economic instability of 
  countries in which Shire does business, as well as changes in 
  foreign currency exchange rates and interest rates, that adversely 
  impact the availability and cost of credit and customer purchasing 
  and payment patterns, including the collectability of customer 
  accounts receivable;
- failure of a marketed product to work effectively or if such a 
  product is the cause of adverse side effects could result in damage
  to the Shire's reputation, the withdrawal of the product and legal 
  action against Shire;
- investigations or enforcement action by regulatory authorities or 
  law enforcement agencies relating to Shire's activities in the 
  highly regulated markets in which it operates may result in 
  significant legal costs and the payment of substantial compensation
  or fines;
- Shire is dependent on information technology and its systems and 
  infrastructure face certain risks, including from service 
  disruptions, the loss of sensitive or confidential information, 
  cyber-attacks and other security breaches or data leakages that 
  could have a material adverse effect on Shire's revenues, financial
  condition or results of operations;
- Shire incurred substantial additional indebtedness to finance the 
  Baxalta acquisition, which may decrease its business flexibility 
  and increase borrowing costs;
- difficulties in integrating Dyax or Baxalta into Shire may lead to 
  the combined company not being able to realize the expected 
  operating efficiencies, cost savings, revenue enhancements, 
  synergies or other benefits at the time anticipated or at all; and 

other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including those risks outlined in "ITEM 1A: Risk Factors" in Shire's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.

All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

please contact:
Investor Relations
Sarah Elton-Farr
seltonfarr@shire.com
+44-1256-894157

Ian Karp
ikarp@shire.com
+1-781-482-9018

Robert Coates
rcoates@shire.com
+44-1256-894874

Media
Gwen Fisher
gfisher@shire.com
+1-484-595-9836

Debbi Ford
debbi.ford@shire.com
+1-617-949-9083

Original-Content von: Shire Pharmaceuticals Group Plc, übermittelt durch news aktuell

Weitere Meldungen: Shire Pharmaceuticals Group Plc

Das könnte Sie auch interessieren: